1. Home
  2. SOWG vs CVRX Comparison

SOWG vs CVRX Comparison

Compare SOWG & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sow Good Inc.

SOWG

Sow Good Inc.

N/A

Current Price

$2.90

Market Cap

69.9M

ML Signal

N/A

Logo CVRx Inc.

CVRX

CVRx Inc.

HOLD

Current Price

$2.96

Market Cap

81.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOWG
CVRX
Founded
2010
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.9M
81.3M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
SOWG
CVRX
Price
$2.90
$2.96
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$10.50
AVG Volume (30 Days)
16.2K
658.9K
Earning Date
05-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.02
EPS
N/A
N/A
Revenue
N/A
$56,651,000.00
Revenue This Year
N/A
$17.17
Revenue Next Year
N/A
$17.69
P/E Ratio
N/A
N/A
Revenue Growth
N/A
10.45
52 Week Low
$0.10
$2.20
52 Week High
$4.45
$11.30

Technical Indicators

Market Signals
Indicator
SOWG
CVRX
Relative Strength Index (RSI) 41.81 41.35
Support Level $2.45 $2.70
Resistance Level $3.65 $3.24
Average True Range (ATR) 0.39 0.18
MACD -0.05 0.07
Stochastic Oscillator 11.60 54.74

Price Performance

Historical Comparison
SOWG
CVRX

About SOWG Sow Good Inc.

Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.

About CVRX CVRx Inc.

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Share on Social Networks: